Small molecule interleukin 17A/A antagonists and antibodies blocking both IL17A/A & IL17A/F demonstrate equivalent degrees of efficacy in preclinical models of skin and joint inflammation
Eric R. Goedken,Zhi Su,Alex Lipovsky,Arun K. Kannan,Katharine L. Chu,Samantha Ciura,Sage E. Foley,Kristine E. Frank,Christian Goess,Sujatha M. Gopalakrishnan,Stephen N. Greszler,Hasan Khan,Laura Leys,Jacob King,Suzanne Mathieu,Sanjay C. Panchal,Stephanie Paulsboe,M. Perham,Ashley L. Ramos,Peter F. Slivka